High-rolling investors have positioned themselves bullish on ImmunityBio IBRX, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in IBRX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for ImmunityBio. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $41,060, and 7 calls, totaling $334,525.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $10.0 for ImmunityBio, spanning the last three months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ImmunityBio's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ImmunityBio's substantial trades, within a strike price spectrum from $3.0 to $10.0 over the preceding 30 days.
ImmunityBio 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IBRX | CALL | TRADE | NEUTRAL | 01/17/25 | $2.2 | $2.1 | $2.15 | $7.50 | $70.5K | 6.1K | 651 |
| IBRX | CALL | TRADE | BEARISH | 06/21/24 | $0.6 | $0.5 | $0.5 | $10.00 | $65.0K | 20.4K | 1.4K |
| IBRX | CALL | TRADE | BULLISH | 01/16/26 | $6.3 | $3.7 | $5.3 | $3.00 | $53.0K | 5 | 100 |
| IBRX | CALL | SWEEP | BEARISH | 06/21/24 | $0.6 | $0.45 | $0.45 | $10.00 | $42.5K | 20.4K | 2.4K |
| IBRX | PUT | SWEEP | BULLISH | 10/18/24 | $2.3 | $2.05 | $2.05 | $7.50 | $41.0K | 693 | 372 |
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
In light of the recent options history for ImmunityBio, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of ImmunityBio
- Trading volume stands at 2,760,420, with IBRX's price down by -0.65%, positioned at $7.7.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 81 days.
Expert Opinions on ImmunityBio
1 market experts have recently issued ratings for this stock, with a consensus target price of $6.0.
- Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for ImmunityBio, targeting a price of $6.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ImmunityBio, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
